Patents by Inventor Mi Yeon Kim

Mi Yeon Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240074965
    Abstract: The present disclosure relates to an ultraviolet light-blocking composition containing a centipede grass extract and a cosmetic composition and, more specifically, to an ultraviolet light-blocking composition comprising a centipede grass (Eremochloa ophiuroides) leaf extract as an active ingredient; and a cosmetic composition containing the ultraviolet light-blocking composition.
    Type: Application
    Filed: January 6, 2022
    Publication date: March 7, 2024
    Applicant: KOREA ATOMIC ENERGY REREARCH INSTITUTE
    Inventors: Byung-Yeoup CHUNG, Hyoung-Woo BAI, Seong-Hee KANG, Sung-Beom LEE, Seung-Sik LEE, Tae-Hoon KIM, Mi-Yeon KIM
  • Patent number: 11787329
    Abstract: Disclosed is a lamp module for an industrial vehicle. The lamp module for an industrial vehicle according to an embodiment of the present utility model can be installed inside a counterweight, unlike the conventional method of embedding in the counterweight, thereby improving workability and assemblability of the operator and improving visibility.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: October 17, 2023
    Assignee: HYUNDAI DOOSAN INFRACORE CO., LTD.
    Inventor: Mi Yeon Kim
  • Patent number: 11701360
    Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK 1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: July 18, 2023
    Assignee: GENUV Inc.
    Inventors: Kang-Yell Choi, Mi-Yeon Kim, Sungho Han
  • Publication number: 20230190967
    Abstract: The present invention relates to: a method for evaluating response to treatment using a MEK 1/2 inhibitor in an individual diagnosed with a neurodegenerative disease; and a composition to be used for the method. Particularly, the method of the present invention comprises measuring, in a biological sample obtained from the individual with a neurodegenerative disease, the concentration of at least one biomarker selected from the group consisting of osteopontin, synaptotagmin-1, apolipoprotein-E, cathepsin B, HLA-DOB (HLA class II histocompatibility antigen, DO beta chain), and neurofilament light chain. According to the present invention, response to the MEK 1/2 inhibitor in the individual diagnosed with a neurodegenerative disease is monitored, and it is thereby possible to obtain useful information for managing the individual, such as determining the possibility of a treatment effect early on and determining whether to continue drug treatment and whether the amount needs to be adjusted.
    Type: Application
    Filed: October 13, 2022
    Publication date: June 22, 2023
    Applicant: GENUV INC.
    Inventors: Sungho Han, Mi-Yeon Kim, Yoon Sun Chun, Hyoung Tae Kim, Jina Park
  • Publication number: 20220265657
    Abstract: The present invention relates to administration methods and dosage regimens for treatment of neurodegenerative diseases using trametinib and markers. The administration methods and dosage regimens induce neural regeneration and changes in gene expression.
    Type: Application
    Filed: May 22, 2020
    Publication date: August 25, 2022
    Inventors: Sung Ho HAN, Mi-Yeon KIM, Yoon Sun CHUN
  • Publication number: 20220266741
    Abstract: Disclosed is a lamp module for an industrial vehicle. The lamp module for an industrial vehicle according to an embodiment of the present utility model can be installed inside a counterweight, unlike the conventional method of embedding in the counterweight, thereby improving workability and assembility of the operator and improving visibility.
    Type: Application
    Filed: February 9, 2022
    Publication date: August 25, 2022
    Inventor: Mi Yeon KIM
  • Publication number: 20210401844
    Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK 1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.
    Type: Application
    Filed: August 31, 2021
    Publication date: December 30, 2021
    Inventors: Kang-Yell CHOI, Mi-Yeon KIM, Sungho HAN
  • Patent number: 11147816
    Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: October 19, 2021
    Assignee: GENUV Inc.
    Inventors: Kang-Yell Choi, Mi-Yeon Kim, Sungho Han
  • Publication number: 20200368239
    Abstract: The present invention relates to administration methods and dosage regimens for treatment of neurodegenerative diseases, in particular ALS, using trametinib. The administration methods and dosage regimens induce neural regeneration and changes in gene expression.
    Type: Application
    Filed: May 21, 2020
    Publication date: November 26, 2020
    Inventors: Sungho HAN, Mi-Yeon KIM, Sun-Young LEE
  • Publication number: 20200046706
    Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.
    Type: Application
    Filed: August 20, 2019
    Publication date: February 13, 2020
    Inventors: Kang-Yell CHOI, Mi-Yeon KIM, Sungho HAN
  • Patent number: 10530029
    Abstract: A modularization of a circulator and a directional coupler used in a wireless communication system comprises: a circulator; and a signal coupler, where the signal coupler does not have directivity by itself, and directivity of the circulator module is controlled by isolation characteristics of the circulator to improve electrical characteristics of a wireless communication system and miniaturize the wireless communication system by applying the electrical characteristics in common with a circulator to modularize the wireless communication system without implementation of a circuit of a directional coupler capable of sampling high-frequency signals.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: January 7, 2020
    Assignee: 3RWAVE CO., LTD.
    Inventors: Yong Ju Ban, Dong Hui Lee, Mi Yeon Kim
  • Patent number: 10485802
    Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: November 26, 2019
    Assignee: GENUV Inc.
    Inventors: Kang-Yell Choi, Mi-Yeon Kim, Sungho Han
  • Patent number: 10179132
    Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: January 15, 2019
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell Choi, Mi-Yeon Kim, Yeong-Mun Kim
  • Publication number: 20180169102
    Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.
    Type: Application
    Filed: February 14, 2018
    Publication date: June 21, 2018
    Inventors: Kang-Yell CHOI, Mi-Yeon Kim, Sungho Han
  • Publication number: 20180159192
    Abstract: A modularization of a circulator and a directional coupler used in a wireless communication system comprises: a circulator; and a signal coupler, where the signal coupler does not have directivity by itself, and directivity of the circulator module is controlled by isolation characteristics of the circulator to improve electrical characteristics of a wireless communication system and miniaturize the wireless communication system by applying the electrical characteristics in common with a circulator to modularize the wireless communication system without implementation of a circuit of a directional coupler capable of sampling high-frequency signals.
    Type: Application
    Filed: April 20, 2016
    Publication date: June 7, 2018
    Inventors: Yong Ju BAN, Dong Hui LEE, Mi Yeon KIM
  • Patent number: 9828339
    Abstract: Provided are biphenyl derivatives having the structure of Formula 1: stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen, halogen, hydroxy, substituted or unsubstituted C1-C6 alkyl, or C1-C6 alkoxy; R2, R3 and R4 are each independently hydrogen, halogen, substituted or unsubstituted amino, nitro, cyano, hydroxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, or —C(O)R6; R5 is hydrogen or C1-C6 alkyl; n is 0 or 1; and R6 is hydrogen or amino, methods for preparing the same, and a pharmaceutical composition containing the same.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: November 28, 2017
    Assignee: DONG-A ST CO., LTD
    Inventors: Soon-Hoe Kim, Weon-Bin Im, Chong-Hwan Cho, Sun-Ho Choi, Jung-Sang Park, Mi-Yeon Kim, Sung-Hak Choi, Min-Jung Lee, Kang-Hun Cho
  • Publication number: 20170209451
    Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.
    Type: Application
    Filed: March 10, 2017
    Publication date: July 27, 2017
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell CHOI, Mi-Yeon KIM, Yeong-Mun KIM
  • Patent number: 9676796
    Abstract: The present invention relates to a novel tricyclic benzoxaborole derivative, a preparation method thereof, and use of antibiotics pharmaceutical composition including the same as an active ingredient.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: June 13, 2017
    Assignee: DONG-A ST CO., LTD.
    Inventors: Soon-Hoe Kim, Weon-Bin Im, Seung-Bum Ha, Jung-Sang Park, Mi-Yeon Kim, Sung-Hak Choi, Hyun-Jung Sung
  • Publication number: 20160346329
    Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.
    Type: Application
    Filed: October 7, 2015
    Publication date: December 1, 2016
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell CHOI, Mi-Yeon Kim, Yeong-Mun Kim
  • Publication number: 20160176816
    Abstract: The present invention provides novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, methods for preparing the same, and a pharmaceutical composition containing the same. The novel biphenyl derivatives, isomers thereof, or pharmaceutically acceptable salts thereof, as disclosed in the present invention, act as muscarinic M3 receptor antagonists, and thus are useful for the prevention or treatment of a disease selected from the group consisting of chronic obstructive pulmonary disease, asthma, irritable bowel syndrome, urinary incontinence, rhinitis, spasmodic colitis, chronic cystitis, Alzheimer's disease, senile dementia, glaucoma, schizophrenia, gastroesophageal reflux disease, cardiac arrhythmia, and hyper-salivation syndromes.
    Type: Application
    Filed: July 17, 2014
    Publication date: June 23, 2016
    Inventors: Soon-Hoe KIM, Weon-Bin IM, Chong-Hwan CHO, Sun-Ho CHOI, Jung-Sang PARK, Mi-Yeon KIM, Sung-Hak CHOI, Min-Jung LEE, Kang-Hun CHO